A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Erasca, Inc.
Incyte Corporation
Pfizer
M.D. Anderson Cancer Center
Quanta Therapeutics
Genentech, Inc.
Boehringer Ingelheim
Bristol-Myers Squibb
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Quanta Therapeutics
University of California, San Diego
Ono Pharmaceutical Co., Ltd.